Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cataract & MIGS cases in North Carolina: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 7% on average (255 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 257 | 72,439 | 40% |
| 2020 | 253 | 63,208 | 43% |
| 2021 | 245 | 67,178 | 48% |
| 2022 | 247 | 73,461 | 52% |
| 2023 | 248 | 75,874 | 56% |
| 2024 | 248 | 74,301 | 59% |
| 2025 from claims | – | 72,823 66,831–77,047 | 61% |
| 2026 forecast | – | 75,851 66,737–87,528 | 62% |
| 2027 forecast | – | 78,678 67,261–93,760 | 62% |
| 2028 forecast | – | 81,563 68,056–99,871 | 63% |
| 2029 forecast | – | 84,502 69,018–105,973 | 64% |
| 2030 forecast | – | 87,491 70,093–112,119 | 65% |
Cataract extraction with IOL, with and without glaucoma stents; the ASC volume engine. Professional codes (what the surgeon bills): CPT 66984, 66982, 66989, 66991, 66987, 66988, 65820, 66174, 66183, 0671T, 0449T.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 15% of the cases CMS names in North Carolina; 128 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 34% hospital outpatient, 59% surgery center, 7% office. The share outside the hospital has moved +12 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 638 | 117,786−2.6%/yr | −2.6%/yr | 53.6 | 88% | 129,100 in 2030+1.5%/yr |
| Florida | 588 | 114,602−2.3%/yr | −2.3%/yr | 50.4 | 95% | 126,900 in 2030+1.7%/yr |
| Virginia | 225 | 73,424+1%/yr | +1%/yr | 69.1 | 87% | 82,800 in 2030+2%/yr |
| Tennessee | 167 | 60,859+2.6%/yr | +2.6%/yr | 85.1 | 93% | 72,000 in 2030+2.8%/yr |
| Georgia | 221 | 47,191−3.3%/yr | −3.3%/yr | 53.6 | 89% | 50,000 in 2030+1%/yr |
| South Carolina | 144 | 45,000+1.8%/yr | +1.8%/yr | 64.6 | 89% | 59,900 in 2030+4.9%/yr |
| Maryland | 198 | 39,250−1.2%/yr | −1.2%/yr | 44.0 | 91% | 41,300 in 2030+0.8%/yr |
| Alabama | 102 | 35,688−2.7%/yr | −2.7%/yr | 79.5 | 83% | 29,500 in 2030−3.1%/yr |
| Oklahoma | 85 | 29,510−2.8%/yr | −2.8%/yr | 60.0 | 81% | 28,700 in 2030−0.5%/yr |
| Kentucky | 91 | 27,713−3.2%/yr | −3.2%/yr | 59.3 | 80% | 29,700 in 2030+1.2%/yr |
| Louisiana | 120 | 22,385−5.1%/yr | −5.1%/yr | 53.7 | 61% | 20,400 in 2030−1.5%/yr |
| Mississippi | 74 | 21,062−3.1%/yr | −3.1%/yr | 55.3 | 96% | 21,400 in 2030+0.3%/yr |
| Arkansas | 64 | 19,041−6%/yr | −6%/yr | 49.6 | 87% | 22,100 in 2030+2.5%/yr |
| Delaware | 21 | 8,893+2%/yr | +2%/yr | 51.3 | 94% | 10,900 in 2030+3.5%/yr |
| West Virginia | 40 | 8,511−8.6%/yr | −8.6%/yr | 40.0 | 46% | 6,820 in 2030−3.6%/yr |
| District of Columbia | 29 | 3,191+3%/yr | +3%/yr | 50.1 | 95% | 4,020 in 2030+3.9%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Vitreoretinal surgery | 33 | 2,261−4%/yr | −4%/yr | 2.30.9× | 36% | 2,170 in 2030−0.7%/yr |
Cataract & MIGS in every state, and its device makers · Every procedure market in North Carolina · Every state · Compare with Texas
Alcon leads with 74% of company spending on these surgeons in 2025, +4 pts on 2024.
In 2025, 20 companies reported engagement with North Carolina’s surgeons worth $828K in consulting, speaking, meals and travel tied to these products, about $3,337 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 46 clearances and approvals in the category, 1 recalled product line. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.
For CPT 66984 (xcapsl ctrc rmvl w/o ecp), commercial plans pay North Carolina’s hospitals a median of $2,276, from $2,276 at the lowest to $2,803 at the highest, across 8 hospitals that publish a price.
Each hospital’s median over its commercial plans, from the machine-readable files hospitals must post; not every hospital is loaded.